Navigation Links
First Patient Enrolled in 'CONNECT' Clinical Trial
Date:9/9/2010

REDWOOD CITY, Calif., Sept. 9 /PRNewswire/ -- Avinger, Inc., a medical device company focused on the development of innovative devices to combat peripheral artery disease, announces the enrollment of the first patient in the CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial.  The CONNECT trial is a prospective, multi-center, non-randomized study intended to evaluate the Wildcat Catheter's ability to cross chronic total occlusions in femoropopliteal lesions.  Patients with peripheral artery disease may have chronic total occlusions which are sometimes difficult to treat with endovascular therapy resulting in either bypass surgery or amputation.  

The ability to cross chronic total occlusions (CTOs) enables subsequent endovascular treatment of peripheral artery disease and is directly related to acute procedural success and favorable long-term outcomes.  The Wildcat Catheter crosses CTO lesions by creating a small channel through the blockage using retractable spiral wedges creating a "corkscrew" effect enabling further treatment of the lesion with therapeutic devices.  The Wildcat Catheter received FDA 510(k) clearance in February 2009 for use as a guidewire support device to access discreet areas of the vasculature. Avinger is conducting this study to secure FDA clearance for an indication specific to crossing CTOs.

"We are very excited by this new technology," said Dr. Thomas Davis of St. John Hospital and Medical Center, who enrolled the first patient in the CONNECT trial. "If we weren't able to cross this CTO with the Wildcat, the only other option for this patient would have been a surgical bypass or amputation.  With the help of this technology we will hopefully be able to change the paradigm of treatment from surgical to endovascular."

The CONNECT study will evaluate 88 PAD patients with femoropopliteal CTO lesions at 15 centers in the US.  Patients will be followed for 30 days post procedure and an independent group of physicians will review the angiography results to determine crossing efficacy and safety.  Conditional FDA approval to conduct this study was received on August 11, 2010.  Co-Principal investigators for the trial are Dr. Thomas Davis of St. John Hospital and Medical Center in Detroit, Michigan and Dr. Laiq Raja of El Paso Cardiology Associates, P.A. and Providence Memorial Hospital in El Paso, Texas.

"Avinger was created to develop technologies that change the way vascular disease is treated today," said Avinger CEO John B. Simpson, PhD, MD.  "The CONNECT trial will provide clinical data to help guide physicians in the use of the Wildcat and provide expanded treatment options for PAD.  We hope that Avinger can play a key role in helping patients facing an amputation keep their leg."

About AvingerFounded in 2007 by John B. Simpson, PhD, MD, Avinger, Inc. (http://www.avinger.com) is developing the next generation of catheter-based technologies for the treatment of cardiovascular and peripheral vascular disease utilizing our core competencies in medical device catheter engineering and intravascular imaging. Avinger Contact John D. Simpson Vice President, Commercial Operations Phone: +1 650 363 2400 jd@avinger.com
'/>"/>

SOURCE Avinger, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
(Date:5/24/2016)... , May 24, 2016 ... den Markt gebracht, die es Ärzten erlaubt, ihre ... zu behandeln: MDLinking kombiniert Live Streaming mit einer ... Umfeld zu kommunizieren. Mediziner in Europa, Afrika, Asien ... sich bereits für die Plattform registriert. ...
Breaking Medicine Technology:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... More than ... so it is not surprising that bariatric surgery has received increased attention in recent ... explains. Of course, when it comes to weight loss, most people are familiar with ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... An influential ... for a third time to shed lights on the variety of topics detailing why ... stories, “Nurse Appreciation” tackles why this career has gone from being in a major ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... the factors of a stroke, which we as a society can control and change. ... a stroke occurs nearly every 40 seconds within the United States. Plus, with an ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to ... who are unaware of the plight of aphasia. In collaboration with the American ... Awareness” campaign. , The link between stroke and aphasia is relatively unknown, but ...
Breaking Medicine News(10 mins):